Latest news with #Cytomegalovirus
Business Upturn
06-08-2025
- Business
- Business Upturn
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032
New York, USA, Aug. 06, 2025 (GLOBE NEWSWIRE) — Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplant procedures, driven by the growing incidence of chronic kidney disease, renal failure, and end-stage renal disease (ESRD), all of which can cause irreversible kidney damage and necessitate transplantation. Furthermore, ongoing advancements in research and development, along with the launch of innovative therapies designed to prevent transplant rejection, are also playing a vital role in propelling market growth. DelveInsight's Renal Transplant Therapeutics Market Insights report provides the current and forecast market analysis, individual leading renal transplant therapeutics companies' market shares, challenges, renal transplant therapeutics market drivers, barriers, trends, and key market renal transplant therapeutics companies in the market. Key Takeaways from the Renal Transplant Therapeutics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global renal transplant therapeutics market during the forecast period. In the drug class segment of the renal transplant therapeutics market, the calcineurin inhibitors category accounted for the largest market share in 2024. Notable renal transplant therapeutics companies such as Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and several others are currently operating in the renal transplant therapeutics market. and several others are currently operating in the renal transplant therapeutics market. In March 2025, Zydus announced the launch of ANVIMO (Letermovir), marking a significant advancement in the prevention of Cytomegalovirus (CMV) infection among kidney transplant recipients. ANVIMO offers a safer, well-tolerated, and effective alternative to existing therapies, with superior safety, fewer side effects, and the potential to enhance post-transplant outcomes, making it a valuable addition to renal transplant care. announced the launch of ANVIMO (Letermovir), marking a significant advancement in the prevention of Cytomegalovirus (CMV) infection among kidney transplant recipients. ANVIMO offers a safer, well-tolerated, and effective alternative to existing therapies, with superior safety, fewer side effects, and the potential to enhance post-transplant outcomes, making it a valuable addition to renal transplant care. In March 2025, Hansa Biopharma AB announced the completion of enrollment for its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label, Phase 3 confirmatory trial in Europe. The study is evaluating one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase, aiming to further validate the therapy's clinical effectiveness and safety. announced the completion of enrollment for its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label, Phase 3 confirmatory trial in Europe. The study is evaluating one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase, aiming to further validate the therapy's clinical effectiveness and safety. In February 2025, Eledon Pharmaceuticals, Inc. announced that its investigational anti-CD40L antibody, tegoprubart, was utilized as a key component of the immunosuppressive regimen in a groundbreaking xenotransplantation procedure. On January 25, 2025, a patient received a genetically modified pig kidney at Massachusetts General Hospital (MGH), with the transplant performed in collaboration with eGenesis, marking a significant milestone in the advancement of cross-species organ transplantation. To read more about the latest highlights related to the renal transplant therapeutics market, get a snapshot of the key highlights entailed in the Global Renal Transplant Therapeutics Market Report Renal Transplant Therapeutics Overview Renal transplant therapeutics encompass a range of pharmacological strategies aimed at ensuring graft survival, minimizing rejection, and managing post-transplant complications. The cornerstone of therapy includes immunosuppressive agents such as calcineurin inhibitors, antiproliferative agents, and corticosteroids. These drugs work synergistically to suppress the immune system and prevent acute and chronic rejection of the transplanted kidney. Innovations in immunosuppressive regimens have significantly improved short-term graft survival rates, although long-term outcomes are still challenged by drug toxicity, infections, and the development of donor-specific antibodies. Emerging therapeutics are now targeting more precise immune pathways, such as co-stimulatory blockers and monoclonal antibodies, to offer more targeted immunosuppression with fewer side effects. Additionally, the field is exploring biomarkers for early detection of rejection and personalized dosing strategies using pharmacogenomics. Efforts are also underway to develop tolerance-inducing therapies that could potentially eliminate the need for lifelong immunosuppression. These advancements, along with supportive therapies to manage comorbidities like hypertension and infections, are shaping a more patient-centric and effective approach to renal transplant care. Renal Transplant Therapeutics Market Insights North America is anticipated to dominate the renal transplant therapeutics market, driven by multiple key factors. These include the increasing incidence of kidney disorders such as chronic kidney disease and end-stage renal disease (ESRD), a growing number of kidney transplant procedures, and a robust healthcare infrastructure. Additionally, major regional players are making significant strides in developing transplant-related therapies. For instance, in October 2024, Biogen announced that its investigational anti-CD38 monoclonal antibody, felzartamab, received Breakthrough Therapy Designation (BTD) from the U.S. FDA for the treatment of late antibody-mediated rejection (AMR) in kidney transplant patients, excluding cases with concurrent T-cell–mediated rejection. As a result, the synergistic effect of rising transplant volumes, high disease burden, and sustained therapeutic innovation is expected to drive substantial market growth in North America from 2025 to 2032. To know more about why North America is leading the market growth in the renal transplant therapeutics market, get a snapshot of the Renal Transplant Therapeutics Market Outlook Renal Transplant Therapeutics Market Dynamics The renal transplant therapeutics market is shaped by a combination of clinical advancements, increasing disease burden, and evolving healthcare infrastructure. The rising global prevalence of CKD and ESRD continues to drive demand for kidney transplantation as a preferred treatment modality. This, in turn, has amplified the need for effective immunosuppressive and anti-rejection therapies. Key therapeutic classes include calcineurin inhibitors, corticosteroids, antiproliferative agents, and newer biologics like monoclonal antibodies, which have significantly improved graft survival rates and reduced rejection episodes. One of the major dynamics influencing the market is the ongoing innovation in immunosuppressive regimens. The development of more selective and targeted therapies is aimed at minimizing long-term complications such as infections, malignancies, and nephrotoxicity, which are commonly associated with conventional immunosuppressants. Moreover, research into personalized medicine approaches, including genetic profiling to predict rejection risk, has opened new avenues for tailored treatment plans that enhance patient outcomes and long-term graft survival. The market is also impacted by the availability and accessibility of transplantation infrastructure, including organ donation systems, surgical facilities, and post-transplant care. High-income regions like North America and Western Europe dominate the market due to advanced healthcare systems, robust transplant programs, and favorable reimbursement policies. In contrast, emerging markets in Asia-Pacific and Latin America are showing growing potential, driven by increasing awareness, improving healthcare access, and government initiatives to strengthen organ donation and transplantation frameworks. Regulatory and policy frameworks play a critical role in shaping the renal transplant therapeutics landscape. Stringent regulations regarding drug approval, pricing, and post-marketing surveillance can both facilitate and hinder market growth. In addition, the presence of biosimilars and generic immunosuppressants has intensified competition, especially in cost-sensitive regions, providing more affordable options but also challenging the market share of originator brands. Lastly, challenges such as organ shortage, high treatment costs, and long-term medication adherence continue to hinder optimal market expansion. Despite these hurdles, the growing pipeline of novel immunomodulatory drugs, the rise of living donor programs, and advancements in transplant diagnostics and monitoring tools suggest a positive outlook for the renal transplant therapeutics market over the coming decade. Get a sneak peek at the renal transplant therapeutics market dynamics @ Renal Transplant Therapeutics Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Renal Transplant Therapeutics Market CAGR ~6% Renal Transplant Therapeutics Market Size by 2032 ~USD 18 Billion Key Renal Transplant Therapeutics Companies Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and others Renal Transplant Therapeutics Market Assessment Renal Transplant Therapeutics Market Segmentation Renal Transplant Therapeutics Market Segmentation By Drug Class: Calcineurin Inhibitors, Interleukin Inhibitors, mTOR Inhibitors, IMPDH Inhibitors, and Others Renal Transplant Therapeutics Market Segmentation By Route of Administration: Oral and Parenteral Renal Transplant Therapeutics Market Segmentation By Modality: Small Molecule and Biologics Renal Transplant Therapeutics Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the renal transplant therapeutics market are set to emerge as the trendsetter explore @ Renal Transplant Therapeutics Analysis Table of Contents 1 Renal Transplant Therapeutics Market Report Introduction 2 Renal Transplant Therapeutics Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Renal Transplant Therapeutics Market Key Factors Analysis 6 Renal Transplant Therapeutics Market Porter's Five Forces Analysis 7 Renal Transplant Therapeutics Market Layout 8 Renal Transplant Therapeutics Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the renal transplant therapeutics market by 2032? Click to get a snapshot of the Renal Transplant Therapeutics Market Analysis Related Reports Interleukin Inhibitors Market Interleukin Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key interleukin inhibitors companies, including AbbVie, Sanofi, Regeneron, Johnson & Johnson, Novartis, among others. mTOR Inhibitors Market mTOR Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key mTOR inhibitors companies, including Novartis, Pfizer, AstraZeneca, Merck, AbbVie, Bristol Myers Squibb, Hoffmann-La Roche, among others. Chronic Kidney Disease Market Chronic Kidney Disease Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CKD companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, among others. Chronic Kidney Disease Pipeline Chronic Kidney Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CKD companies, including AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals, among others. End-Stage Renal Disease Market End-Stage Renal Disease Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ESRD companies, including Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc., Becton, Dickinson and Company, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
The Citizen
28-07-2025
- Health
- The Citizen
Stem Cell Donor Needed for Young Lives at Risk
Registering is free and simple, and if you're between the ages of 17 and 55 and in good health, you could be the match these families are waiting for. DKMS Africa, a non-profit organisation committed to the fight against blood cancer and blood disorders, is appealing to potential donors to help save two young lives. Two-year-old Oyintando and 21-year-old Zachary are urgently searching for matching donors to survive. Two young lives on hold Following numerous hospital visits, Oyintando was initially diagnosed with Cytomegalovirus (CMV), which is a common and usually harmless virus that causes problems in babies and people with weakened immune systems. After six weeks of treatment, a follow-up referral led doctors to finally diagnose him with Wiskott-Aldrich Syndrome. This is a rare, life-changing genetic disorder that weakens the immune system and affects blood clotting. 'I was terrified when I heard the diagnosis,' says his mother, Bonakele, who had lost another child years earlier to similar symptoms. 'The doctors explained everything to me, and over time, I had to come to terms with the reality.' ALSO READ: Baby girl's life saved by surgery 21-year-old Zachary, a third-year student at Nelson Mandela University, had his life change overnight in February 2025. He went on a routine visit to check on low blood pressure but ended up leaving with an Aplastic Anaemia diagnosis. This is a condition where the bone marrow fails to produce enough new blood cells. He now relies on weekly transfusions and has undergone multiple rounds of medication. Unfortunately, none of his family members are suitable donors. You Could Be the Match 'Both Oyintando and Zachary urgently need stem cell transplants, and their survival depends on the generosity of others,' says Palesa Mokomele, head of Community Engagement and Communications at DKMS Africa Ways to help Members of the public can learn more and register as potential donors at The process is free, simple, and non-invasive, and one registration could mean the difference between life and death for patients like Oyintando and Zachary. In different corners of South Africa, two families are holding onto hope, united by a desperate need for a stem cell donor who could give their loved ones a second chance at life.
Yahoo
19-05-2025
- Business
- Yahoo
Saudi Arabia Molecular Blood Typing, Grouping, Infectious Disease NAT Screening Analyzers and Reagents Report 2025
Unlock emerging opportunities in the next five years with this comprehensive report on blood typing and infectious disease screening. Evaluate market strategies, competitor profiles, technological advancements, and develop effective business plans. Discover trends in automated analyzers and genotyping. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "2025 Saudi Arabia Molecular Blood Typing, Grouping, Infectious Disease NAT Screening Analyzers and Reagents-Transfusion Market Opportunities, Competitive Shares, Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Tests Review" has been added to offering. This comprehensive report offers critical insights for current suppliers and potential market entrants in the blood typing and infectious disease screening sectors in Saudi Arabia, aiming to identify and evaluate emerging opportunities over the next five years. This report is an essential tool for industry executives looking to develop robust business, product development, and marketing strategies. The report features detailed test volume and sales forecasts, providing a comparative analysis of major automated and semi-automated analyzers in Saudi Arabia. It includes profiles of leading and up-and-coming competitors, spotlighting specific product and market opportunities for suppliers in the coming years. Key focal points include blood typing and grouping tests (ABO, Antibody Panels, Antigen Typing, among others) and infectious disease screening tests (AIDS, Cytomegalovirus, Hepatitis, etc.). Competitive Assessments Conducts strategic evaluations of major suppliers and emerging market entrants, analyzing their sales, mergers and acquisitions, product portfolios, marketing approaches, and new products in development. Market Segmentation Analysis Delivers test volume and sales forecasts for over 40 blood typing, grouping, and infectious disease screening tests, including NAT assays. Current and Emerging Products Quantifies current and emerging assays in blood typing, grouping, and infectious disease NAT screening. Surveys automated and semi-automated molecular and immunohematology analyzers. Technology Review Evaluates current and emerging technologies, considering their potential applications within the blood banking market. Lists companies engaged in developing or marketing new technologies and products, categorized by test. Detailed assessments of blood group genotyping methodologies are also provided, such as PCR variations and DNA sequencing methods. The report explores innovative platforms like Microarrays utilizing technologies such as BeadChip Array and MALDI-TOF-MS. Strategic Recommendations Highlights new product development prospects for blood typing, grouping, and infectious disease NAT assays and instrumentation that promise significant market appeal. Suggests alternative market penetration strategies and identifies potential market entry barriers and risks. This report serves as a strategic roadmap for stakeholders aiming to secure a competitive edge in the evolving landscapes of blood typing and infectious disease screening. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Associated Press
09-04-2025
- Business
- Associated Press
mRNA Vaccine and Therapeutics (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) Market Industry Trends and Global Forecasts Report 2025-2035
The 'mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions' report has been added to offering. The global mRNA vaccine and therapeutics market is estimated to be worth USD 1.99 billion by 2035, primarily driven by the anticipated approval of mRNA vaccines and therapeutics intended for the treatment of infectious diseases. In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical studies show the efficacy of these platforms which have been published in the last two years across different research articles. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. At present, over 45 industry players are engaged in the development of mRNA drug candidates for a wide range of disease indications. The success of COVID-19 vaccines, growing research activity and the rich pipeline of mRNA drug candidates is likely to drive the global mRNA vaccine and therapeutics market in the coming decade. Several indications, such as Influenza, Respiratory Syncytial Virus, Cytomegalovirus, are the Expected to Drive the mRNA Vaccine and Therapeutics Market Based on the application area, the market is segmented into COVID-19 and other indications. Owing to their proven efficacy against the COVID-19 infection, the vaccines and therapeutics developed for COVID-19 infection have captured the majority of the market share. However, the anticipated approval of mRNA vaccines for other indications is likely to drive the market in the coming decade. Currently, Influenza Segment Occupies the Largest Share of the mRNA Vaccine and Therapeutics Market Based on the target disease indication, the market is segmented into influenza, respiratory syncytial virus infection and cytomegalovirus diseases. It is worth highlighting that the vaccines and therapeutics developed for influenza are likely to drive the market in the coming decade. This can be attributed to the rise in investment in the research and development of influenza vaccines, along with growing awareness among governments and non-profit organizations about the importance of influenza prevention and control. North America Accounts for the Largest Share of the Market Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest of the World. It is worth highlighting that the market for North America holds the maximum share of the mRNA vaccines and therapeutics market. This trend is likely to remain the same in the coming decade. mRNA Vaccine and Therapeutics Market: Key Insights The report delves into the current state of the mRNA vaccine and therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems. The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes. The current market landscape of mRNA vaccine and therapeutics developers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipeline and comply with the evolving industry benchmarks. The growing interest of stakeholders is evident from the surge in partnership activity; clinical trial agreements emerged as the most prevalent partnership model adopted by drug developers. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds. More than 345,000 patients have been recruited / enrolled in clinical trials registered for various mRNA-based therapies, across different geographies. Over 430 patents related to mRNA vaccine and therapeutics have been filed / granted by industry and non-industry stakeholders, indicating the growing intellectual capital in this domain. Big pharma players have undertaken several initiatives, ranging from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market. The projected opportunity for mRNA vaccine and therapeutics market is likely to be driven by the increasing research and development for mRNA-based drugs focused on non-COVID indications. Some Key Players in the mRNA Vaccine and Therapeutics Market include: Arcturus Therapeutics BioNTech CureVac Ethris IMMORNA Moderna Providence Therapeutics RNACure Suzhou Abogen Biosciences Turn Biotechnologies Gennova Innovac Therapeutics Kernal Biologics Pantherna Therapeutics pHion Therapeutics Recode Therapeutics Rejuvenation Technologies RNAimmune Strand Therapeutics Walvax Ziphius Vaccines Primary Research Overview The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders: Business Development Manager, Canvax Senior Director, Business Development, eTheRNA Team Leader, GC Biopharma mRNA Vaccine and Therapeutics Market: Research Coverage Market Sizing and Opportunity Analysis Market Landscape (Drug Therapies) Market Landscape (Drug Developers): Company Competitiveness Analysis Company Profiles Big Pharma Analysis Start-up Health Indexing Clinical Trial Analysis Funding and Investment Analysis Patent Analysis Market Impact Analysis Key Topics Covered: 1. Preface 2. Research Methodology 3. Economic And Other Project Specific Considerations 4. Executive Summary 5. Introduction 6. Market Landscape 7. Competitive Landscape 8. Company Competitiveness Analysis 9. Company Profiles 10. Big Pharma Initiatives 11. Start-Up Health Indexing 12. Clinical Trial Analysis 13. Partnerships And Collaborations 14. Funding And Investment Analysis 15. Patent Analysis 16. Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges 17. Global MRNA Vaccine And Therapeutics Market 18. MRNA Vaccine And Therapeutics Market, By Application Area 19. MRNA Vaccine And Therapeutics Market, By Target Disease Indication 20. MRNA Vaccine And Therapeutics Market, By Geographical Regions 21. Conclusion 22. Executive Insights 23. Appendix 1: Tabulated Data 24. Appendix 2: List Of Companies And Organizations Additional Benefits Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL Copyright Business Wire 2025. PUB: 04/09/2025 09:17 AM/DISC: 04/09/2025 09:17 AM
Yahoo
01-04-2025
- Business
- Yahoo
mRNA Vaccine and Therapeutics Market Report 2025-2035: 430+ Patents Filed, Signaling Robust Growth in mRNA Intellectual Property
The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes. Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds. mRNA Vaccines and Therapeutics Market mRNA Vaccines and Therapeutics Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions" report has been added to offering. The global mRNA vaccine and therapeutics market is estimated to be worth USD 1.99 billion by 2035, primarily driven by the anticipated approval of mRNA vaccines and therapeutics intended for the treatment of infectious diseases. In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical studies show the efficacy of these platforms which have been published in the last two years across different research articles. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. At present, over 45 industry players are engaged in the development of mRNA drug candidates for a wide range of disease indications. The success of COVID-19 vaccines, growing research activity and the rich pipeline of mRNA drug candidates is likely to drive the global mRNA vaccine and therapeutics market in the coming decade. Several indications, such as Influenza, Respiratory Syncytial Virus, Cytomegalovirus, are the Expected to Drive the mRNA Vaccine and Therapeutics Market Based on the application area, the market is segmented into COVID-19 and other indications. Owing to their proven efficacy against the COVID-19 infection, the vaccines and therapeutics developed for COVID-19 infection have captured the majority of the market share. However, the anticipated approval of mRNA vaccines for other indications is likely to drive the market in the coming decade. Currently, Influenza Segment Occupies the Largest Share of the mRNA Vaccine and Therapeutics Market Based on the target disease indication, the market is segmented into influenza, respiratory syncytial virus infection and cytomegalovirus diseases. It is worth highlighting that the vaccines and therapeutics developed for influenza are likely to drive the market in the coming decade. This can be attributed to the rise in investment in the research and development of influenza vaccines, along with growing awareness among governments and non-profit organizations about the importance of influenza prevention and control. North America Accounts for the Largest Share of the Market Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest of the World. It is worth highlighting that the market for North America holds the maximum share of the mRNA vaccines and therapeutics market. This trend is likely to remain the same in the coming decade. mRNA Vaccine and Therapeutics Market: Key Insights The report delves into the current state of the mRNA vaccine and therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems. The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes. The current market landscape of mRNA vaccine and therapeutics developers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipeline and comply with the evolving industry benchmarks. The growing interest of stakeholders is evident from the surge in partnership activity; clinical trial agreements emerged as the most prevalent partnership model adopted by drug developers. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds. More than 345,000 patients have been recruited / enrolled in clinical trials registered for various mRNA-based therapies, across different geographies. Over 430 patents related to mRNA vaccine and therapeutics have been filed / granted by industry and non-industry stakeholders, indicating the growing intellectual capital in this domain. Big pharma players have undertaken several initiatives, ranging from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market. The projected opportunity for mRNA vaccine and therapeutics market is likely to be driven by the increasing research and development for mRNA-based drugs focused on non-COVID indications. Some Key Players in the mRNA Vaccine and Therapeutics Market include: Arcturus Therapeutics BioNTech CureVac Ethris IMMORNA Moderna Providence Therapeutics RNACure Suzhou Abogen Biosciences Turn Biotechnologies Gennova Innovac Therapeutics Kernal Biologics Pantherna Therapeutics pHion Therapeutics Recode Therapeutics Rejuvenation Technologies RNAimmune Strand Therapeutics Walvax Ziphius Vaccines Primary Research Overview The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders: Business Development Manager, Canvax Senior Director, Business Development, eTheRNA Team Leader, GC Biopharma mRNA Vaccine and Therapeutics Market: Research Coverage Market Sizing and Opportunity Analysis Market Landscape (Drug Therapies) Market Landscape (Drug Developers): Company Competitiveness Analysis Company Profiles Big Pharma Analysis Start-up Health Indexing Clinical Trial Analysis Funding and Investment Analysis Patent Analysis Market Impact Analysis Key Topics Covered: 1. Preface 2. Research Methodology 3. Economic And Other Project Specific Considerations 4. Executive Summary 5. Introduction 6. Market Landscape 7. Competitive Landscape 8. Company Competitiveness Analysis 9. Company Profiles 10. Big Pharma Initiatives 11. Start-Up Health Indexing 12. Clinical Trial Analysis 13. Partnerships And Collaborations 14. Funding And Investment Analysis 15. Patent Analysis 16. Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges 17. Global MRNA Vaccine And Therapeutics Market 18. MRNA Vaccine And Therapeutics Market, By Application Area 19. MRNA Vaccine And Therapeutics Market, By Target Disease Indication 20. MRNA Vaccine And Therapeutics Market, By Geographical Regions 21. Conclusion 22. Executive Insights 23. Appendix 1: Tabulated Data 24. Appendix 2: List Of Companies And Organizations Additional Benefits Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team Free Updated report if the report is 6-12 months old or older For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachments mRNA Vaccines and Therapeutics Market mRNA Vaccines and Therapeutics CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
